Brain metastases (BrM) represent the most common adult intracranial malignancy and herald poor survival. The annual incidence in the United States alone exceeds 200,000 cases. Ultimately, 20 to 40% of patients with solid cancers will develop BrM over the course of their disease, a frequency that is increasing as we gain more effective control of extracranial disease. Over the past decade, BrM have thus evolved into a leading cause of both morbidity and mortality from cancer. Despite this emergent dilemma, few BrM-specific therapies exist, and there is a compelling case for programmatic, collaborative approaches toward BrM management and research.
The goal of this Research Topic will be to present the latest clinical opinions, approaches, and research strategies aimed squarely at benefiting adult patients with brain metastases. A focus on providing multidisciplinary views (i.e. medical oncology, radiation oncology, neurosurgery, and palliative care) of the problem will be offered.
Contributions may take the form of reviews, opinion pieces, or original research (which can range from basic science to retrospective analyses to prospective clinical trials). Contributions will be judged for their capacity to alter current practice and provide new insight into understanding, preventing, or treating adult brain metastasis. Topics of interest include (but are not limited to) the following:
-Epidemiology
-Building center-level multidisciplinary approaches
-Novel mechanistic insights and pathways
-Evidence for best clinical approaches and strategies
-Innovative techniques / procedures
-Novel therapeutics
-Leptomeningeal disease
-Quality of Life Improvements / Neuropsychology / Palliative Care
*Note: If bioinformatics papers are submitted, they must include validation in clinical specimens or functional validation in vitro and/or in vivo.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Brain metastases (BrM) represent the most common adult intracranial malignancy and herald poor survival. The annual incidence in the United States alone exceeds 200,000 cases. Ultimately, 20 to 40% of patients with solid cancers will develop BrM over the course of their disease, a frequency that is increasing as we gain more effective control of extracranial disease. Over the past decade, BrM have thus evolved into a leading cause of both morbidity and mortality from cancer. Despite this emergent dilemma, few BrM-specific therapies exist, and there is a compelling case for programmatic, collaborative approaches toward BrM management and research.
The goal of this Research Topic will be to present the latest clinical opinions, approaches, and research strategies aimed squarely at benefiting adult patients with brain metastases. A focus on providing multidisciplinary views (i.e. medical oncology, radiation oncology, neurosurgery, and palliative care) of the problem will be offered.
Contributions may take the form of reviews, opinion pieces, or original research (which can range from basic science to retrospective analyses to prospective clinical trials). Contributions will be judged for their capacity to alter current practice and provide new insight into understanding, preventing, or treating adult brain metastasis. Topics of interest include (but are not limited to) the following:
-Epidemiology
-Building center-level multidisciplinary approaches
-Novel mechanistic insights and pathways
-Evidence for best clinical approaches and strategies
-Innovative techniques / procedures
-Novel therapeutics
-Leptomeningeal disease
-Quality of Life Improvements / Neuropsychology / Palliative Care
*Note: If bioinformatics papers are submitted, they must include validation in clinical specimens or functional validation in vitro and/or in vivo.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.